CAR-T细胞疗法市场（按目标抗原、治疗应用和地区）：未来预测（2026-2032）

CAR-T细胞疗法市场评估（2026-2032）

癌症发生率不断上升，尤其是白血病和淋巴瘤等骨髓恶性肿瘤，而CAR-T细胞疗法正是有效标靶治疗这些疾病的标靶。此外，基因编辑技术和定製药物的进步将使治疗更加精准有效，预计到2024年，这类癌症的市场规模将达到369亿美元，到2032年将达到1,916亿美元。

肿瘤学研究资金的增加和监管部门的积极核准正在加速这些治疗方法的开发和商业化。患者对创新疗法的需求以及 Kymriah 和 Yescarta 等早期 CAR-T 细胞疗法的成功进一步推动了市场扩张，预计 2026 年至 2032 年的复合年增长率约为 63.82%。

CAR-T细胞疗法市场定义/概述

CAR-T细胞疗法是一种免疫疗法，透过基因改造患者的T细胞来表达嵌合体抗原受体(CAR)，使其能够更有效地靶向和攻击癌细胞。其主要用于治疗白血病、淋巴瘤和多发性骨髓瘤等骨髓恶性肿瘤。此治疗方法已显示出良好的疗效，尤其适用于对先前治疗方法未产生反应的患者。 CAR-T细胞疗法的未来发展方向包括：扩大对固体癌的应用；提高安全性和有效性；降低治疗成本；以及透过新型生产和输送系统提高可及性。

癌症发生率的上升会推动CAR-T细胞治疗市场的发展吗？

癌症发生率的上升是推动CAR-T细胞疗法市场发展的关键因素。随着全球癌症发生率的上升，对创新有效治疗方法的需求也日益增长。根据世界卫生组织 (WHO) 预测，到2040年，癌症确诊人数将达到2,950万，其中白血病和淋巴瘤等骨髓恶性肿瘤将发挥关键作用。癌症负担的日益加重推动了人们对CAR-T细胞疗法的兴趣和投资，该疗法提供个人化的治疗方案，并在临床试验中显示出良好的疗效。

有鑑于新型癌症治疗的迫切需求，各国政府和医疗机构正在推动CAR-T细胞疗法的研究和核准。 2024年3月，FDA加快了针对多种癌症的新型CAR-T细胞疗法的核准流程，彰显了其致力于扩大患者获得这些创新疗法的管道的承诺。此外，随着研发投入的加大以及生技公司和研究机构的通力合作，CAR-T细胞疗法产业预计将大幅扩张。随着癌症发生率的上升以及对更优治疗方法的持续需求，预计到2030年，全球CAR-T细胞疗法市场规模将达到380亿美元。

细胞激素释放症候群（CRS）等副作用的增加是否会阻碍CAR-T细胞治疗市场的成长？

细胞激素释放症候群 (CRS) 是 CAR-T 细胞疗法常见且严重的副作用，其发生率不断上升可能会阻碍市场扩张。当 CAR-T 细胞在输注过程中过度激活，释放大量发炎细胞激素时，就会发生 CRS，这会导致高烧、低血压、呼吸问题，严重时会导致器官衰竭。 CRS 的不可预测性和严重性引起了医疗专业人员、患者和监管机构的担忧，影响了公众对 CAR-T 细胞疗法的认知和接受度。治疗 CRS 需要精心护理，包括使用托珠单抗和皮质类固醇等免疫抑制药物，这可能会增加本已很高的治疗费用，并进一步限制患者获得治疗的机会。

慢性鼻窦炎 (CRS) 早期检测和管理的进步有助于降低风险。研发部门正在开发更安全、更不容易引发 CRS 的下一代 CAR-T 细胞疗法。此外，监测和应对 CRS 的临床指南也在不断发展，缓解了一些担忧。然而，持续存在严重副作用的可能性仍然是更广泛市场成长的障碍，尤其是在医疗基础设施欠发达且加护治疗昂贵的地区。

目录

第一章：全球CAR-T细胞治疗市场简介

• 市场概览
• 分析范围
• 先决条件

第二章执行摘要

第三章 已验证的市场研究分析方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

第四章 全球CAR-T细胞治疗市场展望

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 波特五力模型
• 价值链分析

5. 全球CAR-T细胞治疗市场（以标靶抗原）

• 概述
• CD19
• HER1
• BCMA
• CD33

6. 全球CAR-T细胞治疗市场（依治疗应用）

• 概述
• 急性淋巴性白血病
• 大肠直肠癌
• 慢性淋巴性白血病
• 肝细胞癌

7. 全球CAR-T细胞治疗市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 其他地区 (ROW)
  • 拉丁美洲
  • 中东和非洲

第八章全球CAR-T细胞治疗市场竞争格局

• 概述
• 各公司市场排名
• 主要发展策略

第九章 公司简介

• CARsgen Therapeutics, Ltd
• Novartis International AG
• Pfizer, Inc.
• Kite Pharma, Inc
• Legend Biotech
• Juno Therapeutics

第十章 附录

• 相关分析

CAR T-Cell Therapy Market Valuation - 2026-2032

The increasing incidence of cancer, particularly hematologic malignancies such as leukemia and lymphoma, which CAR T-cell treatments efficiently target. Furthermore, advances in gene-editing technology and customized medicine are allowing for more precise and effective therapies is fuelling the USD 36.9 Billion in 2024 and reaching USD 191.6 Billion by 2032.

Rising funding for oncology research, along with favorable regulatory approvals, is accelerating the development and commercialization of these therapies. Patient demand for innovative treatments and the success of early CAR T therapies, such as Kymriah and Yescarta, are further fueling market expansion is grow at a CAGR of about 63.82% from 2026 to 2032.

Car T Cell Therapy Market: Definition/ Overview

CAR T-cell treatment is a type of immunotherapy in which a patient's T-cells are genetically modified to express chimeric antigen receptors (CARs), allowing them to more effectively target and attack cancer cells. Its main applications are to treat blood malignancies such as leukemia, lymphoma, and multiple myeloma. The therapy has produced promising outcomes, particularly in individuals who have not responded to previous therapies. The future of CAR T-cell therapy includes expanding its application to solid tumors, improving safety and efficacy, lowering treatment costs, and increasing accessibility through novel manufacturing and delivery systems.

Will Growing Prevalence of Cancer Propelling the CAR T Cell Therapy Market?

The rising incidence of cancer is a crucial element driving the CAR T-cell treatment market. As cancer rates climb around the world, there is an increased desire for innovative and effective therapies. According to the World Health Organization (WHO), cancer diagnoses are anticipated to reach 29.5 million by 2040, with hematologic malignancies like leukemia and lymphoma playing a significant role. This growing burden has sparked increased interest and investment in CAR T-cell treatments, which provide individualized therapy choices and have demonstrated encouraging results in clinical trials.

Governments and healthcare organizations recognize the critical need for novel cancer medicines and are thus promoting the research and approval of CAR T-cell treatments. In March 2024, the FDA hastened the clearance process for new CAR T therapies targeting several cancer types, demonstrating a commitment to expanding patient access to these innovative treatments. Furthermore, with large investments in research and development, as well as joint efforts between biotech businesses and research institutes, the CAR T-cell treatment industry is predicted to expand dramatically. The global CAR T-cell therapy market is expected to reach $38 billion by 2030, owing to the increasing frequency of cancer and the continued need for better treatments.

Will Rising Side Effects of Cytokine Release Syndrome (CRS) Hinder the Growth of the CAR T Cell Therapy Market?

Rising incidence of cytokine release syndrome (CRS), a common and serious side effect of CAR T-cell therapy, may impede market expansion. CRS arises when CAR T-cells become over-activated during infusion, resulting in a huge release of inflammatory cytokines that can induce high fevers, low blood pressure, respiratory problems, and, in severe cases, organ failure. The unpredictability and severity of CRS have created concerns among healthcare practitioners, patients, and regulatory agencies, influencing public perception and uptake of CAR T-cell therapy. Managing CRS necessitates careful care, including the use of immunosuppressive medicines such as tocilizumab and corticosteroids, which might increase the already high treatment expenses, further limiting patient accessibility.

Advances in CRS early identification and management techniques are helping to reduce dangers. Researchers are developing next-generation CAR T-cell therapies that are designed to be safer and less likely to cause CRS. Furthermore, clinical guidelines for monitoring and responding to CRS are evolving, which may allay some concerns. However, the continuous potential of severe side effects remains a barrier to broader market growth, particularly in places with underdeveloped healthcare infrastructure or where intensive care is too expensive.

Category-Wise Acumens

Will Rising Demand of CD19 Antigen Propel the CAR T Cell Therapy Market?

The growing demand for CD19-targeted CAR T-cell treatments is likely to greatly boost the market. CD19 is a well-known antigen for treating B-cell malignancies, specifically acute lymphocytic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). The success of CD19-targeted therapies such as Kymriah (Novartis) and Yescarta (Gilead/Kite) has led to widespread acceptance, with the CD19 sector dominating the market. In June 2023,Gilead Sciences announced substantial rise in Yescarta sales, citing increased demand in the United States and Europe as more treatment centers accept the drug. The continuous success of these medicines has confirmed CD19 as a key market growth driver.

For instance, in April 2024, the US FDA granted Kymriah expedited permission to treat a broader group of patients with relapsed or refractory ALL, increasing access to the medication. This regulatory support demonstrates the increasing awareness of CD19 treatments' efficacy. Furthermore, continued research to increase safety and efficacy, combined with excellent clinical outcomes, ensures that the increasing demand for CD19-targeted medicines will continue to drive the CAR T-cell therapy industry.

The fastest-growing segment, is BCMA (B-cell maturation antigen), which is gaining popularity due to its efficacy in treating multiple myeloma. With novel BCMA-targeted medicines such as Abecma entering the market, this segment is projected to expand rapidly in the future years.

Will Rising Usage Acute Lymphatic Leukemia (ALL) Therapies Fuel the CAR T Cell Therapy Market?

The increasing use of CAR T-cell treatments for acute lymphatic leukemia (ALL) is likely to drive market expansion. Kymriah (Novartis), a CAR T-cell therapy licensed for pediatric and young adult patients with relapsed or refractory ALL, has demonstrated extraordinary success in attaining remission in many situations when previous treatments have failed. In May 2023, Novartis reported a surge in demand for Kymriah due to its success in treating ALL, particularly among younger patients. As the first FDA-approved CAR T-cell therapy, Kymriah has established a strong precedent, encouraging additional investment and research into ALL-targeted medicines, which is likely to drive market growth.

In March 2024, the European Medicines Agency (EMA) upgraded Kymriah's permission to treat a broader range of ALL patients, making it more accessible throughout Europe. This regulatory support, combined with continued advances in ALL treatments, sets the sector for rapid expansion. With greater patient awareness, better clinical outcomes, and regulatory support, the adoption of CAR T-cell treatments for ALL will continue to drive the overall CAR T-cell therapy market.

Chronic lymphocytic leukemia (CLL) is the fastest-growing segment, owing to increased research and clinical studies involving CAR T-cell therapy. As treatment options for CLL improve, this market is likely to rise substantially, reflecting increased demand and the development of more effective medicines.

Country/Region-wise

Will Rising Adoption of Advanced Therapies in North America Drive the CAR T Cell Therapy Market?

The increasing use of improved therapeutic alternatives and a supportive regulatory framework. The American Cancer Society estimates that 1.9 million new cancer cases would be diagnosed in 2023, offering a large potential patient pool for CAR T cell therapy. In March 2024, the United States Food and Drug Administration (FDA) authorized two additional CAR T cell therapies for treating certain types of blood malignancies, increasing the total number of CAR T cell products approved in the United States to nine. In January 2024, Bristol Myers Squibb announced a 45% year-over-year rise in sales of its CAR T cell therapy medicines, totaling USD 1.2 Billion in revenue. The National Cancer Institute has also in 2024, it will increase its financing for cell therapy research by 25%, with USD 500 Million set aside particularly for CAR T cell therapy development and clinical trials.

According to a Cell & Gene Therapy Catapult analysis, the number of CAR T cell therapy clinical studies in North America grew by 35% in 2023 compared to 2022, with over 500 trials currently underway. Furthermore, the Centers for Medicare & Medicaid Services reported that insurance coverage for CAR T cell therapies expanded by 30% in 2023, improving access to these treatments. These developments, coupled with increasing success rates in clinical trials and growing physician acceptance, indicate that North America will continue to lead the global CAR T cell therapy market growth.

Will Increasing Healthcare Infrastructure in Asia Pacific Propel the CAR T Cell Therapy Market?

The growing healthcare infrastructure in Asia-Pacific is expected to boost the CAR T-cell treatment market significantly. Many countries, including China and India, are investing considerably in improving their healthcare systems, which includes the construction of advanced treatment facilities and increased access to cutting-edge therapies. For instance, in April 2024, the Chinese government announced a significant financial commitment to support oncology research and increase access to CAR T-cell therapy in rural areas. This investment is likely to increase the availability of novel treatments, making them more accessible to a larger patient population and boosting the growth of the CAR T-cell therapy market in the area.

Furthermore, the Asia-Pacific market is seeing greater collaboration between local biotech businesses and multinational pharmaceutical corporations, which is helping to improve the development and marketing of CAR T cell therapies. Gilead Sciences established a partnership with a top Chinese biotech firm in February 2024 to develop and commercialize CAR T-cell medicines specifically for the Asian market. The goal of this collaboration is to speed the commercialization of CAR T-cell therapeutics by using the region's developing healthcare infrastructure and expertise. According to Verified Market Research, the CAR T-cell therapy market is expected to grow at a compound annual growth rate (CAGR) of more than 63.82% between 2024 and 2031, owing to infrastructure improvements and strategic partnerships, highlighting the region's potential in this rapidly evolving market.

Competitive Landscape

The competitive landscape of the CAR T-cell therapy market is characterized by the presence of emerging biotechnology firms and smaller pharmaceutical companies focusing on innovative therapies. These players often collaborate with academic institutions and research organizations to develop novel treatments. They also benefit from partnerships with larger companies for funding and commercialization. With advancements in gene editing and manufacturing processes, these smaller firms are gaining traction by addressing unmet clinical needs, targeting diverse cancer types, and optimizing the safety and efficacy of CAR T-cell therapies.

Some of the prominent players operating in the CAR T cell therapy market Include:

CARsgen Therapeutics, Ltd.

Novartis International AG

Pfizer, Inc.

Kite Pharma, Inc.

Legend Biotech

Juno Therapeutics.

Latest Developments

In March 2024, Bristol Myers Squibb announced positive clinical trial findings for Abecma, a CAR T-cell treatment targeting multiple myeloma. According to the business, the medication displayed significant efficacy in patients with relapsed and refractory disease, indicating that it has the potential to gain broader market acceptability.

In January 2024, Celgene reported positive findings from a Phase II clinical trial of their CAR T-cell treatment for ALL. The trial demonstrated a high overall remission rate, highlighting the potential of CAR T treatments in both juvenile and adult populations.

Car T-Cell Therapy Market, By Category

• Targeted Antigen:
• CD 19
• HER1
• BCMA
• CD33
• Therapeutic Application:
• Acute Lymphocytic Leukemia
• Colorectal Cancer
• Chronic Lymphocytic Leukemia
• Hepatocellular Carcinoma
• Region:
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL CAR T-CELL THERAPY MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL CAR T-CELL THERAPY MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL CAR T-CELL THERAPY MARKET, BY TARGETED ANTIGEN

• 5.1 Overview
• 5.2 CD19
• 5.3 HER1
• 5.4 BCMA
• 5.5 CD33

6 GLOBAL CAR T-CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION

• 6.1 Overview
• 6.2 Acute Lymphocytic Leukemia
• 6.3 Colorectal Cancer
• 6.4 Chronic Lymphocytic Leukemia
• 6.5 Hepatocellular Carcinoma

7 GLOBAL CAR T-CELL THERAPY MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL CAR T-CELL THERAPY MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 CARsgen Therapeutics, Ltd
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Novartis International AG
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Pfizer, Inc.
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Kite Pharma, Inc
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Legend Biotech
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Juno Therapeutics
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments

10 Appendix

• 10.1 Related Research